Canna_Business
2日前
The Maryland Department of Agriculture allows the use of neem oil on medical cannabis during the flowering phase, but this raises significant health and safety concerns. Neem oil, while widely recognized as an organic pesticide, can transform into hazardous compounds when exposed to high heat, such as during smoking. Studies have shown that heating neem oil can release harmful byproducts, including acrolein, a known respiratory irritant, and other toxic substances that can lead to severe health risks like lung inflammation, irritation, or long-term respiratory damage.
The issue is exacerbated by the lack of oversight from federal agencies like the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), which do not regulate pesticide residues on cannabis. Unlike traditional agriculture, cannabis cultivation operates in a gray area where state regulations vary widely, and federal guidelines are absent. This regulatory gap leaves consumers vulnerable to unintended exposure to harmful chemicals, especially in states like Maryland, where neem oil use is explicitly permitted during sensitive growth phases like flowering.
Medical cannabis patients, many of whom already have compromised immune or respiratory systems, are at heightened risk. These individuals may unknowingly inhale toxic residues that exacerbate their conditions, potentially leading to severe health complications. The situation is not only a public health crisis but also a legal time bomb, as affected individuals could pursue lawsuits against growers, dispensaries, or even state regulatory bodies for failing to protect consumer safety.
This growing concern underscores the urgent need for stricter testing protocols and unified federal regulations to address pesticide use in cannabis cultivation. Consumers should be cautious and informed about the potential risks of smoking cannabis treated with neem oil and advocate for more robust safeguards to protect public health.
#NeemOil #ConsumerSafety #PublicHealth #ATF #LegalConcerns #CannabisRegulation #MarylandCannabis
Canna_Business
3週前
How Companies Are Selling THCa Online Without a License:
The 2018 Farm Bill has created a legal loophole for selling THCa online. THCa, which is non-psychoactive until heated, can be sold legally if it tests under 0.3% Delta-9 THC on a dry weight basis. This allows companies to bypass traditional cannabis licensing and state regulations.
Key Points:
2018 Farm Bill: Permits cannabis products with under 0.3% Delta-9 THC.
THCa Products: Non-psychoactive until heated but converts to Delta-9 THC when smoked or vaped.
No License Needed: THCa meets legal THC limits, avoiding the need for a cannabis license.
Consumer Impact: Consumers can buy THCa products online, evading stricter state cannabis laws.
Summary: The 2018 Farm Bill has inadvertently allowed THCa products to be sold legally online by staying within THC limits, despite their psychoactive potential when heated.
For example,
https://www.reddit.com/r/CultoftheFranklin/
________________________________________________________________________________
Explaining THCa and THC: The 2018 Farm Bill Loophole...
- THCa vs. THC: THCa is non-psychoactive but converts to THC (which causes a high) when heated through smoking, vaping, or cooking.
- 2018 Farm Bill Loophole: The bill legalized hemp with less than 0.3% THC but didn’t mention THCa, allowing high-THCa cannabis to be sold legally if it tests below 0.3% THC before being heated.
- Online vs. Dispensary Sales: Both sell THCa-rich cannabis. Dispensaries can sell any THC level, while online sellers must comply with the 0.3% THC limit until the product is heated.
- Decarboxylation: Heating (through smoking, vaping, or cooking) decarbs (converts) THCa into active THC.
Canna_Business
1月前
How Companies Are Selling THCa Online Without a License:
The 2018 Farm Bill has created a legal loophole for selling THCa online. THCa, which is non-psychoactive until heated, can be sold legally if it tests under 0.3% Delta-9 THC on a dry weight basis. This allows companies to bypass traditional cannabis licensing and state regulations.
Key Points:
2018 Farm Bill: Permits cannabis products with under 0.3% Delta-9 THC.
THCa Products: Non-psychoactive until heated but converts to Delta-9 THC when smoked or vaped.
No License Needed: THCa meets legal THC limits, avoiding the need for a cannabis license.
Consumer Impact: Consumers can buy THCa products online, evading stricter state cannabis laws.
Summary: The 2018 Farm Bill has inadvertently allowed THCa products to be sold legally online by staying within THC limits, despite their psychoactive potential when heated.
For example,
https://www.reddit.com/r/CultoftheFranklin/
Canna_Business
2月前
How Companies Are Selling THCa Online Without a License:
The 2018 Farm Bill has created a legal loophole for selling THCa online. THCa, which is non-psychoactive until heated, can be sold legally if it tests under 0.3% Delta-9 THC on a dry weight basis. This allows companies to bypass traditional cannabis licensing and state regulations.
Key Points:
2018 Farm Bill: Permits cannabis products with under 0.3% Delta-9 THC.
THCa Products: Non-psychoactive until heated but converts to Delta-9 THC when smoked or vaped.
No License Needed: THCa meets legal THC limits, avoiding the need for a cannabis license.
Consumer Impact: Consumers can buy THCa products online, evading stricter state cannabis laws.
Summary: The 2018 Farm Bill has inadvertently allowed THCa products to be sold legally online by staying within THC limits, despite their psychoactive potential when heated.
For example,
https://www.prestonherbco.com/products/100-ozs
Canna_Business
3月前
The 2018 Farm Bill has created a legal loophole for selling THCa online...
THCa, which is non-psychoactive until heated, can be sold legally if it tests under 0.3% Delta-9 THC on a dry weight basis. This allows companies to bypass traditional cannabis licensing and state regulations.
Key Points:
2018 Farm Bill: Permits cannabis products with under 0.3% Delta-9 THC.
THCa Products: Non-psychoactive until heated but converts to Delta-9 THC when smoked or vaped.
No License Needed: THCa meets legal THC limits, avoiding the need for a cannabis license.
Consumer Impact: Consumers can buy THCa products online, evading stricter state cannabis laws.
Summary: The 2018 Farm Bill has inadvertently allowed THCa products to be sold legally online by staying within THC limits, despite their psychoactive potential when heated.
For example,
https://www.prestonherbco.com/products/100-ozs
Canna_Business
3月前
Sublingual Tincture: THC + CBD + Coconut Oil
Components:
• THC: Euphoric, pain relief, relaxation.
• CBD: Non-intoxicating, reduces anxiety, inflammation, breaks down tumors and cysts.
• Coconut Oil: Carrier oil, enhances absorption, contains monolaurin (antimicrobial, helps bypass the blood-brain barrier and acts as an emulsifier).
Extraction Process:
Decarboxylate:
• Preheat oven to 220°F.
• Bake ground cannabis for 30 minutes.
Usage: Start with 1-2 drops and increase as needed. Store in a cool, dark place.
Summary: A simple, effective way to deliver cannabinoids and terpenes with quick onset and controlled dosage. Perfect for those seeking therapeutic benefits without the delay of digestion.
Brokemillwright
9月前
Over done? You know my bearish stance so no. If that was a wave 3 up wave 4 down went past the level I googled which is the .382@ 8.91 ill be curious to see if it can make 5 waves up, 3 from what i gather isnt bullish and that could have been a 3 move up. Here's something I typed out that might confuse you, I struggle just as bad as the next. There is a difference between Fibonacci retracements and Fibonacci projections. I think retracements are the normal levels and projections are more like the extremes. I've had decent luck with projections but have been trying to use both.
That's a tough one. Measuring Fibonacci projections from the high just below $10 on sep. 18 to the low of sub $5 in October to the latest high gives downward levels of (previous reply had the upwards levels that it's seemed to align with for the time being)
.236/ 9.56
.382/ 8.85
.5/ 8.27
.618/ 7.70
.786/ 6.83
1/ 5.84
1.618/ 2.83
I see volume nodes around here and low 7s.
I'll be honest, I don't know what to make of that pattern. Could be in a first wave 4 of 5 up if it start to find support then after wave 5 it could be wave 2 down in 3 moves and the good wave 3- typically longest and strongest either up or down. I'm still new with lots to learn, and have gathered the most evidence a sustainable long term bottom is in is after the lowest low you get 5 waves up and a 3 wave move down (ABC). I don't know if this is a W Pattern, kinda looked like one so I could see that pump up happening. After that it's not clear with my limited knowledge, so take ot all with a grain of salt and the market will do what it wants regardless lol.
From the IPO low of $20.61 to the $56 high I have a retracement of the 1.5 fib $2.88 and the 1.618 of -$1.30 again, my treading water knowledge knows that the .618 and 1.618 levels are most often touched and I haven't figured out counting waves so I pretty much rely on those two basics. Negative price would be a reverse split or bankruptcy I'm guessing but that 1.5 fib retracement of $2.88 is awfully close to the recent 1.618 fib extension of $2.83 then I factor in my view on the global economy (pessimistic by nature) and wouldn't be surprised to see that happening, unless we get the 5 wave move up and 3 down that ive been looking for on about any of my stocks. I use trading view to practice charting when they do half off sale around Thanksgiving And follow more trading online, crypto savy, and market makers on YouTube as they all either use Fibonacci or some sort of it and I'm becoming a believer in it. Northstar bad charts is the other trading publication I pay for and they teach risk management and have a learning section that I haven't checked out nearly enough. My last one is Bonner private research and you can watch the sales pitch on YouTube under Americas nightmare winter. Some of it is pretty boring but the gist of energy crisis causes by the green energy scam alings with my view. They have a portfolio of "maximum safety" with 60% commodies split between high dividend energy stocks and prescious metals and 40% in 1-3 month Treasury bills getting paid 5.5% interest waiting for a crash to buy high quality bargins. Lots of good free info from the YouTube guys I mentioned. Sorry for the long winded rant but I'm a believer in the Fibonacci and like to share good info when I have it.
Brokemillwright
10月前
Your alive! Of course you speak and it drops too! DOOHHHHH gotta be quicker than that! Sorry man, you've been bullish since $12+ when I said don't catch a falling knife over a year ago...... And look where it dropped. I don't know it all but think I have a semi decent grasp on things with Lots to learn. Lots of pain coming for the market still, I'd avoid this like the plague if I wanted to grow my portfolio. Pick up some urnm,gold,xop, pbr/a, usefull stuff with dividends. Bonner private research is a good paid newsletter and Northstar bad charts is another that does a decent job at teaching risk management, trends and charting. I will try the worchersire one day. Ever had a chuck eye steak? Best part of the ribeye for chuck price
$Green$
11月前
"Congressman Steve Cohen (D-TN) Tells DEA To Reschedule Marijuana 'As Swiftly As Possible'
A Democratic congressman is calling on the Drug Enforcement Administration (DEA) to complete its marijuana review "as swiftly as possible" and abide by the U.S. Department of Health and Human Services's (HHS) recommendation to reclassify cannabis under Schedule III.
In a letter sent to DEA Administrator Anne Milgram on Thursday, Rep. Steve Cohen (D-TN) said he "appreciated the opportunity" to address the scheduling review process during a House subcommittee hearing she testified at last July but that he wants the agency to move more quickly to complete the job.
Since that hearing, HHS completed its scientific assessment of cannabis and advised DEA to move it from Schedule I to Schedule III under the Controlled Substances Act (CSA).
"I urge you, in the strongest possible way, to follow through on HHS's recommendation," Cohen said. "It is critical that the DEA's review is expeditious and that your agency quickly initiate the rulemaking process."
"Marijuana never belonged on Schedule I. Its inclusion resulted in harsh and disproportionate prison sentences, particularly for communities of color," he wrote. "Nearly half the states have already legalized marijuana for recreational use by ballot measure."
The lawmaker told Milgram she has a "historic opportunity to make make meaningful progress as Congress works on legislation to deschedule marijuana under the Controlled Substances Act and address some of the inequities caused by this misguided and discriminatory policy."
"The DEA should move as swiftly as possible on this effort, and I hope to see a Notice of Proposed Rulemaking on this issue soon," Cohen, who has long advocated for an end to federal prohibition, wrote.
While the Congressional Research Service (CRS) said it is "likely" that the agency will follow the HHS recommendation and move marijuana to Schedule III, DEA has emphasized that it has "final authority" over the matter and could make any scheduling decision, regardless of the HHS findings.
"DEA has the final authority to schedule, reschedule, or deschedule a drug under the Controlled Substances Act, after considering the relevant statutory and regulatory criteria and HHS's scientific and medical evaluation," the agency said in a letter to lawmakers last month. "DEA is now conducting its review."
DEA's statement came in response to an earlier letter from 31 bipartisan lawmakers, led by Rep. Earl Blumenauer (D-OR), that implored DEA to consider the "merits" of legalization as it carried out its review. That initial letter also criticized the limitations of simply placing cannabis in Schedule III, as opposed to fully removing the plant from CSA control.
Also, despite the furor over the ongoing rescheduling review, outside observers still know little about HHS's justification for its recommendation that cannabis be moved to Schedule III. While the agency sent hundreds of pages of explanation to DEA as part of its rescheduling recommendation, those documents have so far only been released in highly redacted form, with little to no indication of the federal health agency's findings related to possible medical benefits, addictive potential or any other aspect of the policy decision.
DEA has received a number of messages from different sides of the cannabis policy debate in recent months, including a recent letter from 29 former U.S. attorneys who urged the Biden administration to leave cannabis in Schedule I.
Last month, the governors of six U.S. statesâ??Colorado, Illinois, New York, New Jersey, Maryland and Louisianaâ??sent a letter to Biden calling on the administration to reschedule marijuana by the end of last year.
Meanwhile, six former DEA heads and five former White House drug czars sent a letter to the attorney general and current DEA administrator voicing opposition to the top federal health agency's recommendation to reschedule marijuana. They also made a questionable claim about the relationship between drug schedules and criminal penalties in a way that could exaggerate the potential impact of the incremental reform.
Signatories include DEA and Office of National Drug Control Policy heads under multiple administrations led by presidents of both major parties.
In October, Advocates and lawmakers who support cannabis reform marked the one-year anniversary of Biden's mass marijuana pardon and scheduling directive this month by calling on him to do moreâ??including by expanding the scope of relief that his pardon had and by expressly supporting federal legalization.
Two GOP senators, including the lead Republican sponsor of a marijuana banking bill that cleared a key committee in September, also filed legislation late last year to prevent federal agencies from rescheduling cannabis without tacit approval from Congress.
A coalition of 14 Republican congressional lawmakers, meanwhile, has urged DEA to "reject" the top federal health agency's recommendation to reschedule marijuana and instead keep it in the most restrictive category under the CSA.
Separately, DEA recently announced that it is taking another shot at banning two psychedelics after abandoning its original scheduling proposal in 2022, teeing up another fight with researchers and advocates who say the compounds hold therapeutic potential.
The agency has separately warned Georgia pharmacies that dispensing THC is unlawful because it remains a Schedule I drug after the state became the first in the U.S. to allow pharmacies to sell medical marijuana, with nearly 120 facilities applying to sell cannabis oil.
Meanwhile, DEA recently affirmed that spores that produce so-called magic mushrooms are not, on their own, federally prohibited prior to germination.